Physician profile
John Joseph Oconnell
NPI 1952455768
$5,779.14
in general payments reported to CMS, 2019-2025
27 companies · $130 in 2025
The $130 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,645 · 2020: $236 · 2022: $201 · 2023: $313 · 2024: $254 · 2025: $130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $696.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $696.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,500.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $163.17 | 2022-2024 | Tagrisso |
| Takeda Pharmaceuticals U.S.A., INC. | $140.18 | 2020-2024 | Fruzaqla |
| Pfizer INC. | $135.57 | 2023-2025 | |
| Boston Scientific Corporation | $131.24 | 2019-2025 | Spaceoar System |
| E.R. Squibb & Sons, L.L.C. | $114.08 | 2020 | |
| Servier Pharmaceuticals LLC | $86.73 | 2024-2025 | |
| Seagen INC. | $48.41 | 2022 | |
| Tactile Systems Technology INC | $46.92 | 2023-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Daiichi Sankyo INC. | $44.67 | 2023-2024 | Enhertu |
| Sumitomo Pharma America, INC. | $43.66 | 2023 | Orgovyx |
| Bayer Healthcare Pharmaceuticals INC. | $43.54 | 2023-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $40.58 | 2023 | Imbruvica |
| Incyte Corporation | $31.73 | 2023-2024 | Jakafi |
| Stemline Therapeutics INC. | $25.55 | 2023 | Orserdu |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $23.08 | 2024 | Ultomiris |
| Eisai INC. | $22.91 | 2023 | |
| Blueprint Medicines Corporation | $19.07 | 2023 | Ayvakit |
| Blue Earth Diagnostics | $17.15 | 2024 | |
| Novocure INC. | $16.35 | 2025 | Optune Lua (Novottf-200t) |
| Brainlab, INC. | $15.69 | 2019 | |
| Kyowa Kirin, INC. | $15.47 | 2023 | Poteligeo |
| Sobi, INC | $14.04 | 2022 | |
| Emd Serono, INC. | $13.98 | 2022 | |
| Morphosys, US INC. | $13.43 | 2023 | Monjuvi |
| Olympus America INC. | $11.94 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Oconnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.